Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nicole L. Byers"'
Autor:
Iain B. McInnes, Nicole L. Byers, Richard E. Higgs, Jonathan Lee, William L. Macias, Songqing Na, Robert A. Ortmann, Guilherme Rocha, Terence P. Rooney, Thomas Wehrman, Xin Zhang, Steven H. Zuckerman, Peter C. Taylor
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. Methods Peripheral blood mononuclear cells from healthy dono
Externí odkaz:
https://doaj.org/article/9199674c675b4aa38a99899ed7156b79
Autor:
Justin Stebbing, Venkatesh Krishnan, Stephanie de Bono, Silvia Ottaviani, Giacomo Casalini, Peter J Richardson, Vanessa Monteil, Volker M Lauschke, Ali Mirazimi, Sonia Youhanna, Yee‐Joo Tan, Fausto Baldanti, Antonella Sarasini, Jorge A Ross Terres, Brian J Nickoloff, Richard E Higgs, Guilherme Rocha, Nicole L Byers, Douglas E Schlichting, Ajay Nirula, Anabela Cardoso, Mario Corbellino, the Sacco Baricitinib Study Group
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 8, Pp 1-15 (2020)
Abstract Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID‐19 infection via prop
Externí odkaz:
https://doaj.org/article/1380cc483c5c41d9b6607430fabfaf22
Autor:
Daniel J Wallace, Michelle A Petri, Thomas Dörner, Stephanie de Bono, Robert J Benschop, Ernst R Dow, Damiano Fantini, Richard E Higgs, Guilherme Rocha, Brenda Crowe, Nicole L Byers, Maria E Silk, Robert W Hoffman
Publikováno v:
Lupus Science and Medicine, Vol 7, Iss 1 (2020)
Objective To characterise the molecular pathways impacted by the pharmacologic effects of the Janus kinase (JAK) 1 and JAK2 inhibitor baricitinib in SLE.Methods In a phase II, 24-week, randomised, placebo-controlled, double-blind study (JAHH), RNA wa
Externí odkaz:
https://doaj.org/article/e5cc766cafc64ce9bf61c760b2589fcd
Autor:
Volker M. Lauschke, Guilherme Rocha, Jorge A. Ross Terres, Venkatesh Krishnan, Sonia Youhanna, Justin Stebbing, Vanessa Monteil, Silvia Ottaviani, Antonella Sarasini, Anabela Cardoso, Yee-Joo Tan, Fausto Baldanti, Brian J. Nickoloff, Stephanie de Bono, Nicole L. Byers, Mario Corbellino, Ali Mirazimi, Peter J. Richardson, Douglas E Schlichting, Richard E. Higgs, Giacomo Casalini, Ajay Nirula
Publikováno v:
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 12, Iss 8, Pp n/a-n/a (2020)
EMBO Molecular Medicine, Vol 12, Iss 8, Pp n/a-n/a (2020)
Baricitinib, is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI)‐algorithms, to be useful for COVID‐19 infection via a proposed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012ab82ec2fb307eb4bacaff9fff6f73
https://doi.org/10.15252/emmm.202012697
https://doi.org/10.15252/emmm.202012697
Autor:
Daniel J. Wallace, Robert W Hoffman, Thomas Dörner, Josef S Smolen, Ernst R. Dow, Richard E. Higgs, Damiano Fantini, Nicole L. Byers, Michelle Petri, Guilherme Rocha, Brenda J. Crowe, Maria E Silk, Stephanie de Bono, Yoshiya Tanaka, Robert J. Benschop
Publikováno v:
Oral presentations.
Background Baricitinib, an oral selective Janus kinase (JAK)1 and 2 inhibitor, resulted in significant clinical improvements in patients with active systemic lupus erythematosus (SLE) receiving standard background therapy in the phase 2 study JAHH (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a08f765ca5cf0080a948354ef4ae6acb
https://doi.org/10.1136/lupus-2020-eurolupus.18
https://doi.org/10.1136/lupus-2020-eurolupus.18
Autor:
S Na, Terence Rooney, William L. Macias, Peter C. Taylor, Thomas Wehrman, R Ortmann, Xin Zhang, Jonathan A. Lee, Iain B. McInnes, Steven H. Zuckerman, Richard E. Higgs, Guilherme Rocha, Nicole L. Byers
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Background The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. Methods Peripheral blood mononuclear cells from healthy donors were i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237c9f93dc57c1a2560a726fcd0871d4
https://pubmed.ncbi.nlm.nih.gov/31375130
https://pubmed.ncbi.nlm.nih.gov/31375130
Autor:
Stephanie de Bono, William L. Macias, Maher Issa, Veronica Rogai, Nicole L. Byers, Peter C. Taylor, Paul Emery, Douglas E Schlichting, Iain B. McInnes, L. Chen, Steven H. Zuckerman, Terence Rooney, Yoshiya Tanaka
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.). 70(12)
Objective: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9837221c07ecc813d586d6a028fc4c73
https://pubmed.ncbi.nlm.nih.gov/30058141
https://pubmed.ncbi.nlm.nih.gov/30058141